For instance, BCMA/GPRC5D-CAR-NK cells can effectively lyse BCMA-negative MM cells, leading to improved antitumor efficacy in in vivo and ex vivo models. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.